Advertisement
New Zealand markets closed

  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     

  • NZD/USD

    0.5938
    +0.0001 (+0.02%)
     

  • NZD/EUR

    0.5540
    -0.0006 (-0.11%)
     

  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     

  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     

  • OIL

    82.80
    -0.01 (-0.01%)
     

  • GOLD

    2,320.60
    -17.80 (-0.76%)
     

  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     

  • DAX

    18,088.70
    -48.95 (-0.27%)
     

  • Hang Seng

    17,318.76
    +117.49 (+0.68%)
     

  • NIKKEI 225

    37,818.11
    -641.97 (-1.67%)
     

  • NZD/JPY

    92.2880
    +0.1730 (+0.19%)
     

Zoetis Announces Date for 2023 Investor Day

Business Wire
·2-min read

PARSIPPANY, N.J., May 01, 2023--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will host an Investor Day on Thursday, May 25, 2023, at the New York Stock Exchange featuring Kristin Peck, Chief Executive Officer; Wetteny Joseph, Chief Financial Officer; Robert Polzer, Ph.D., President of Research and Development; and other members of the Zoetis executive team. Zoetis will provide an update on the company’s strategy to deliver long-term profitable growth and value for shareholders, followed by a Q&A session.

The event will begin at 9:00 a.m. ET and conclude at approximately 12:30 p.m. ET. A live webcast of the investor day presentations, along with supporting materials, will be available to the general public on the day of the event on the Zoetis Investor Relations website. Information on pre-registering for the webcast is available today.

In-person attendance is by invitation only and advance registration is required. Institutional investors and analysts interested in attending should contact one of the company’s Investor Relations contacts listed on this press release.

About Zoetis

As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers and ranchers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $8.1 billion in 2022 with approximately 13,800 employees. For more information, visit www.zoetis.com.

ADVERTISEMENT

ZTS-COR
ZTS-IR

View source version on businesswire.com: https://www.businesswire.com/news/home/20230501005082/en/

Contacts

Media:
Bill Price
1-973-443-2742 (o)
william.price@zoetis.com

Kristen Seely
1-973-443-2777 (o)
kristen.seely@zoetis.com

Investors:
Steve Frank
1-973-822-7141 (o)
steve.frank@zoetis.com

Nick Soonthornchai
1-973-443-2792 (o)
nick.soonthornchai@zoetis.com